Operating Income (Loss) in USD of PMV Pharmaceuticals, Inc. from 2018 to Q3 2025

Taxonomy & unit
us-gaap: USD
Description
The net result for the period of deducting operating expenses from operating revenues.
Summary
PMV Pharmaceuticals, Inc. quarterly/annual Operating Income (Loss) history and growth rate from 2018 to Q3 2025.
  • PMV Pharmaceuticals, Inc. Operating Income (Loss) for the quarter ending September 30, 2025 was -$22.5M, a 2.9% decline year-over-year.
  • PMV Pharmaceuticals, Inc. Operating Income (Loss) for the twelve months ending September 30, 2025 was -$92.1M, a 16.4% decline year-over-year.
  • PMV Pharmaceuticals, Inc. annual Operating Income (Loss) for 2024 was -$85.4M, a 6.63% decline from 2023.
  • PMV Pharmaceuticals, Inc. annual Operating Income (Loss) for 2023 was -$80.1M, a 4.01% decline from 2022.
  • PMV Pharmaceuticals, Inc. annual Operating Income (Loss) for 2022 was -$77M, a 32.2% decline from 2021.
Operating Income (Loss), Trailing 12 Months (USD)
Operating Income (Loss), Quarterly (USD)
Operating Income (Loss), YoY Quarterly Growth (%)
Operating Income (Loss), Annual (USD)
Operating Income (Loss), YoY Annual Growth (%)

PMV Pharmaceuticals, Inc. Quarterly Operating Income (Loss) (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q3 2025 -$92.1M -$22.5M -$634K -2.9% Jul 1, 2025 Sep 30, 2025 10-Q 2025-11-12
Q2 2025 -$91.5M -$22.9M -$2.71M -13.4% Apr 1, 2025 Jun 30, 2025 10-Q 2025-08-07
Q1 2025 -$88.8M -$21.6M -$3.34M -18.3% Jan 1, 2025 Mar 31, 2025 10-Q 2025-05-09
Q4 2024 -$85.4M -$25.2M -$6.27M -33.2% Oct 1, 2024 Dec 31, 2024 10-K 2025-03-03
Q3 2024 -$79.2M -$21.9M -$2.26M -11.5% Jul 1, 2024 Sep 30, 2024 10-Q 2025-11-12
Q2 2024 -$76.9M -$20.2M -$48K -0.24% Apr 1, 2024 Jun 30, 2024 10-Q 2025-08-07
Q1 2024 -$76.9M -$18.2M +$3.26M +15.2% Jan 1, 2024 Mar 31, 2024 10-Q 2025-05-09
Q4 2023 -$80.1M -$18.9M +$2.26M +10.7% Oct 1, 2023 Dec 31, 2023 10-K 2025-03-03
Q3 2023 -$82.4M -$19.6M -$253K -1.31% Jul 1, 2023 Sep 30, 2023 10-Q 2024-11-07
Q2 2023 -$82.1M -$20.1M -$2.24M -12.5% Apr 1, 2023 Jun 30, 2023 10-Q 2024-08-08
Q1 2023 -$79.9M -$21.5M -$2.86M -15.4% Jan 1, 2023 Mar 31, 2023 10-Q 2024-05-09
Q4 2022 -$77M -$21.2M -$2.69M -14.6% Oct 1, 2022 Dec 31, 2022 10-K 2025-03-03
Q3 2022 -$74.4M -$19.4M -$4.28M -28.3% Jul 1, 2022 Sep 30, 2022 10-Q 2023-11-09
Q2 2022 -$70.1M -$17.9M -$4.84M -37.1% Apr 1, 2022 Jun 30, 2022 10-Q 2023-08-09
Q1 2022 -$65.2M -$18.6M -$6.95M -59.5% Jan 1, 2022 Mar 31, 2022 10-Q 2023-05-10
Q4 2021 -$58.3M -$18.5M -$7.97M -75.9% Oct 1, 2021 Dec 31, 2021 10-K 2024-02-29
Q3 2021 -$50.3M -$15.1M -$6.4M -73.5% Jul 1, 2021 Sep 30, 2021 10-Q 2022-11-08
Q2 2021 -$43.9M -$13.1M -$4.97M -61.4% Apr 1, 2021 Jun 30, 2021 10-Q 2022-08-09
Q1 2021 -$39M -$11.7M -$4.02M -52.5% Jan 1, 2021 Mar 31, 2021 10-Q 2022-05-10
Q4 2020 -$34.9M -$10.5M Oct 1, 2020 Dec 31, 2020 10-K 2023-03-01
Q3 2020 -$8.7M -$2.26M -35.1% Jul 1, 2020 Sep 30, 2020 10-Q 2021-11-12
Q2 2020 -$8.09M Apr 1, 2020 Jun 30, 2020 10-Q 2021-08-13
Q1 2020 -$7.65M Jan 1, 2020 Mar 31, 2020 10-Q 2021-05-14
Q3 2019 -$6.44M Jul 1, 2019 Sep 30, 2019 10-Q 2020-11-13

PMV Pharmaceuticals, Inc. Annual Operating Income (Loss) (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed
2024 -$85.4M -$5.32M -6.63% Jan 1, 2024 Dec 31, 2024 10-K 2025-03-03
2023 -$80.1M -$3.09M -4.01% Jan 1, 2023 Dec 31, 2023 10-K 2025-03-03
2022 -$77M -$18.7M -32.2% Jan 1, 2022 Dec 31, 2022 10-K 2025-03-03
2021 -$58.3M -$23.4M -66.8% Jan 1, 2021 Dec 31, 2021 10-K 2024-02-29
2020 -$34.9M -$8.31M -31.2% Jan 1, 2020 Dec 31, 2020 10-K 2023-03-01
2019 -$26.6M -$7.75M -41% Jan 1, 2019 Dec 31, 2019 10-K 2022-03-01
2018 -$18.9M Jan 1, 2018 Dec 31, 2018 10-K 2021-03-03
* An asterisk sign (*) next to the value indicates that the value is likely invalid.